OptimizeRx Q2 Revenue Falls 30% to $20.5M, Reaffirms FY26 Guidance
OPRX sits 55% above its 52-week low of $4.54.
Summary
OptimizeRx reported Q2 2026 revenue of $20.5 million, down 30% year-over-year from $29.2 million, with a GAAP net loss of $(0.7) million and adjusted EBITDA of $4.9 million. Management reaffirmed full-year 2026 guidance of $95-$100 million in revenue and $21-$25 million in adjusted EBITDA. The company completed a $35 million debt refinancing and has repaid $8.3 million of principal since inception. The revenue drop is concentrated among a small number of customers, while other customer segments show increased investment. Additionally, OptimizeRx named Andy D'silva as the next Chief Financial Officer.
At the time of this announcement, OPRX was trading at $7.04 on NASDAQ in the Technology sector, with a market capitalization of approximately $132.1M. The 52-week trading range was $4.54 to $22.25. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.